BLIS Technologies Limited (NZE:BLT)

Market Cap	34.54M +58.8%
Revenue (ttm)	14.71M +16.2%
Net Income	692.00K -17.4%
EPS	0.00 -23.7%
Shares Out	1.28B
PE Ratio	54.00
Forward PE	19.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,166,445
Open	0.0250
Previous Close	0.0240
Day's Range	0.0250 - 0.0270
52-Week Range	0.0140 - 0.0270
Beta	0.68
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 18, 2026

About BLIS Technologies

BLIS Technologies Limited develops and sells probiotics in New Zealand, the Asia Pacific, Europe, the Middle East, Africa, and North America. It offers BLIS K12, an oral probiotic that supports ear, nose, and throat health, as well as immunity and bad breath; BLIS M18, an oral probiotic for teeth and gums health; and BLIS Q24, a probiotic that balances the skin microbiome and restores skin’s health. The company’s products are used in various health areas, including ear, nose, throat, immune, dental, and skin, as well as pet oral. It exports its...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 43
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: BLT

Financial Performance

In fiscal year 2026, BLIS Technologies's revenue was 14.71 million, an increase of 16.16% compared to the previous year's 12.67 million. Earnings were 692,000, a decrease of -17.42%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error